LifeStance Health Group, Inc. (LFST) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.41%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 7.75×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 4.41% | Share-based compensation / revenue. Period ending 2026-06-30. $69.95M ÷ $1.58B × 100 ≈ 4.41% |
| Interest coverage · 12 months | 7.75× | Operating income ÷ reported interest expense. $78.43M ÷ $10.11M ≈ 7.75× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 1.58B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 69.95M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 78.43M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 10.11M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.58B | $69.95M | $78.43M | $10.11M | (m) | 4.41% | 7.75× | Reported |
| 2026-03-31 | (m) | $1.49B | $71.32M | $44.83M | $10.38M | (m) | 4.77% | 4.32× | Reported |
| 2025-12-31 | (m) | $1.42B | $74.70M | $24.15M | $11.66M | (m) | 5.24% | 2.07× | Reported |
| 2025-09-30 | (m) | $1.37B | $74.14M | $7.12M | $18.18M | (m) | 5.42% | 0.39× | Reported |
| 2025-06-30 | (m) | $1.32B | $70.74M | $-240.00K | $20.78M | (m) | 5.37% | -0.01× | Reported |
| 2025-03-31 | (m) | $1.28B | $74.17M | $-13.24M | $23.70M | (m) | 5.78% | -0.56× | Reported |
| 2024-12-31 | (m) | $1.25B | $76.17M | $-31.61M | $26.54M | (m) | 6.09% | -1.19× | Reported |
| 2024-09-30 | (m) | $1.21B | $80.94M | $-64.94M | $22.67M | (m) | 6.71% | -2.86× | Reported |
| 2024-06-30 | (m) | $1.16B | $87.58M | $-139.35M | $22.73M | (m) | 7.57% | -6.13× | Reported |
| 2024-03-31 | (m) | $1.10B | $96.10M | $-171.81M | $22.03M | (m) | 8.71% | -7.80× | Reported |
| 2023-12-31 | (m) | $1.06B | $99.39M | $-189.13M | $21.22M | (m) | 9.41% | -8.91× | Reported |
| 2023-09-30 | (m) | $1.00B | $113.66M | $-202.88M | $20.85M | (m) | 11.32% | -9.73× | Reported |
| 2023-06-30 | (m) | $959.09M | $127.01M | $-167.36M | $19.57M | (m) | 13.24% | -8.55× | Reported |
| 2023-03-31 | (m) | $909.04M | $151.44M | $-179.42M | $21.58M | (m) | 16.66% | -8.31× | Reported |
| 2022-12-31 | (m) | $859.54M | $187.43M | $-210.17M | $19.93M | (m) | 21.81% | -10.55× | Reported |
| 2022-09-30 | (m) | $630.18M | $260.87M | $-277.92M | $18.36M | (m) | 41.40% | -15.13× | Reported |
| 2022-06-30 | (m) | $412.62M | $346.68M | $-363.75M | $17.68M | (m) | 84.02% | -20.58× | Reported |
| 2022-03-31 | (m) | $61.41M | $318.69M | $-350.32M | $33.72M | (m) | 518.97% | -10.39× | Reported |
| 2021-12-31 | (m) | $1.45M | $259.44M | $-286.35M | $38.91M | (m) | 17954.26% | -7.36× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $143.27M | $2.06M | $5.86M | $27.74M | (m) | 1.44% | 0.21× | Reported |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-05-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $212.52M | $54.00K | $15.24M | $5.41M | (m) | 0.03% | 2.82× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |